AAP Grand Rounds Subscribe to Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 15 No. 2, February 2006
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neimark, E.
Right arrow Articles by LeLeiko, N. S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Neimark, E.
Right arrow Articles by LeLeiko, N. S.
Related Collections
Right arrow Clinical Pharmacology and Therapeutics
Right arrow Gastroenterology and Nutrition
Right arrow Infectious Diseases

AAP Grand Rounds 15:13-14 (2006)
© 2006 American Academy of Pediatrics

GASTROENTEROLOGY AND NUTRITION

New Treatment Combination Effective for Chronic Hepatitis C

Source: Gonzalez-Peralta R, Kelly D, Haber B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology. 2005;42:1010–1018.[Medline]

The first 20% of the full text of this article appears below.

Chronic hepatitis C virus (HCV) infection is usually asymptomatic in children, but significant liver disease including chronic hepatitis, cirrhosis, and hepatocellular carcinoma may occur. The International Pediatric Hepatitis C Therapy Group evaluated the efficacy, safety, and pharmacokinetics of interferon alpha-2b in combination with ribavirin for the treatment of chronic HCV infection in children. The primary efficacy endpoint was sustained virological response, defined by undetectable serum HCV RNA 24 weeks after completion of therapy. All efficacy and safety analyses were performed on the intent-to-treat population. The study, conducted in 29 centers in Europe, Canada, Israel, and the United States between January 1998 and November 2001, had 3 phases. In phase 1, the authors determined the optimal . . . [Full Text of this Article]

Ezequiel Neimark, MD and Neal S. LeLeiko, MD, PhD, FAAP
Pediatrics, Brown School of Medicine, and Pediatric Gastroenterology, Nutrition and Liver Disease, Hasbro Children’s Hospital, Providence, RI

 





HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Academy of Pediatrics.